Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by Croupier2on Feb 25, 2014 1:50pm
283 Views
Post# 22248945

If you want to add, you have until

If you want to add, you have until the first week of April

CD47 will be big at the AACR ths year

And SCT will share the spotlight with Weissman ...

SCT said that where they will present data that differientiate them from Standford (and from what I hear from the doctors, SCT will steal the show)

Here is the stage
https://www.abstractsonline.com/Plan/SSResults.aspx

Presentation Search Results
Select/Clear All Presentations per Page

Presentation Session
Wed, Apr 9, 8:00 AM - 12:00 PM
5011/1 - Cancer immunotherapy targeting CD47: Wild type SIRPaFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding
Robert A. Uger, Karen Dodge, Xinli Pang, Penka S. Petrova. Trillium Therapeutics Inc./Stem Cell Therapeutics Corp., Toronto, ON, Canada Poster Session
PO.IM02.02. Immune Checkpoint Inhibition
Wed, Apr 9, 8:00 AM - 12:00 PM
Mon, Apr 7, 1:00 - 5:00 PM
1911/6 - NF-?B mediated CD47 upregulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma
Jessica Lo, Eunice Yuen Ting Lau, Irene Oi Lin Ng, Terence Kin Wah Lee. State Key Laboratory for Liver Research, Department of Pathology, Li Ka Shing Faculty of Medicine,The University of Hong Kong, Hong Kong Poster Session
PO.TB02.01. Cancer Stem Cell Phenotype and Function 1
Mon, Apr 7, 1:00 - 5:00 PM
Tue, Apr 8, 1:00 - 5:00 PM
4082/10 - CD47 blockade to enhance adaptive anti-tumor immune responses
Katie L. Anderson, Daisuke Ito, Debra C. Lins, Julie M. Curtsinger, Matthew F. Mescher, Jaime F. Modiano. University of Minnesota, Minneapolis, MN Poster Session
PO.IM01.04. Adaptive Immunity and Immune Regulation
Tue, Apr 8, 1:00 - 5:00 PM
Mon, Apr 7, 1:00 - 5:00 PM
2434/5 - Therapeutic targeting of CD47 regulates cell bioenergetics and autophagy to reduce breast tumor growth and protect against anthracycline-mediated cardiac toxicity
David R. Soto-Pantoja, John M. Sipes, Arunima Ghosh, Maria J. Merino, David D. Roberts. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD Poster Session
PO.MCB09.05. Metabolic Pathways 2
Mon, Apr 7, 1:00 - 5:00 PM
Mon, Apr 7, 8:45 - 9:15 AM
PL02-02 - Investigating inhibition of the CD47 "don't eat me" signal to enable tumor phagocytic removal and augmented cross presentation to T cells
. Stanford Univ. School of Medicine, Stanford, CA Plenary Session
PL02. Targeted Immunotherapy: Mobilizing the Immune System Against Cancer
Mon, Apr 7, 8:15 - 10:15 AM
Tue, Apr 8, 8:00 AM - 12:00 PM
3629/2 - Overcoming macrophage immunosuppression in small cell lung cancer with high-affinity SIRPa variants
Kipp Weiskopf, Peter J. Schnorr, Nadine Jahchan, Aaron M. Ring, Roy L. Maute, Anne K. Volkmer, Jens-Peter Volkmer, Kenan C. Garcia, Julien Sage, Irving L. Weissman. Stanford University School of Medicine, Stanford, CA Poster Session
PO.IM02.06. Immune Modulation in the Tumor Microenvironment
Tue, Apr 8, 8:00 AM - 12:00 PM
Wed, Apr 9, 8:00 AM - 12:00 PM
5318/14 - LC-MS/MS quantification of proteins CD47 and SIRPA in cell subtypes selected by flow cytometry from blood
Carmen Fernandez-Metzler1, Renold Capocasale2. 1PharmaCadence Analytical Services, Hatfield, PA;2Flowmetric, Doylestown, PA Poster Session
PO.MCB12.02. Proteomics
Wed, Apr 9, 8:00 AM - 12:00 PM
Tue, Apr 8, 1:00 - 5:00 PM
3886/2 - Clec12a: A new AML stem cell-associated antigen
Viviana Guadagnuolo, Enrica Imbrogno, Andrea Ghelli Luserna di Rorà, Antonella Padella, Giorgia Simonetti, Emanuela Ottaviani, Cristina Papayannidis, Ilaria Iacobucci, Anna Ferrari, Simona Soverini, Giovanni Martinelli. L. & A. Seragnoli, Bologna, Italy Poster Session
PO.TB02.06. Cancer Stem Cell Phenotype, Function, and Targeting
Tue, Apr 8, 1:00 - 5:00 PM
Tue, Apr 8, 1:00 - 5:00 PM
3959/24 - Depleting macrophage or blocking cell fusion machinery ameliorates intestine fibrosis after radiation
Ya-Hui Chang, Hui-Ju Ch’ang, Li-Mei Lin. National Health Research Institution, Tainan City, Taiwan Poster Session
PO.TB09.01. Modifiers and Predictors of Tumor Response to Radiation and Other DNA-Damaging Agents 1
Tue, Apr 8, 1:00 - 5:00 PM
Wed, Apr 9, 8:00 AM - 12:00 PM
4820/8 - Exploring metastatic capacity and targets on circulating epithelial cells (CEC) in early and late breast cancer
Leo Habets, Sr.1, Bettina Frenken1, Ilham El Ghali1, Mahmoud Danaei2, Manfred Kusche2, Uwe Peisker3, Katharina Pachmann4. 1Metares e.V, Aachen, Germany; 2Brustzentrum Aachen Kreis Heinsberg, Aachen, Germany; 3Brustzentrum Aachen Kreis Heinsberg, Erkelenz, Germany; 4TZB Bayreuth, Bayreuth, Germany Poster Session
PO.TB04.09. Circulating and Disseminated Tumor Cells as Predictors of Tumor Metastasis
Wed, Apr 9, 8:00 AM - 12:00 PM
Tue, Apr 8, 8:00 AM - 12:00 PM
3044/13 - Cancer associated fibroblasts-derived HGF regulates cancer stem cell-like properties in hepatocellular carcinoma
Yuen Ting Lau, Jessica Lo, Irene Oi Lin Ng, Terence Kin Wah Lee. The University of Hong Kong, Hong Kong Poster Session
PO.TB02.04. Cancer Stem Cell Phenotype and Function 2
Tue, Apr 8, 8:00 AM - 12:00 PM
Mon, Apr 7, 1:00 - 5:00 PM
2661/22 - Patient-derived breast cancer targeting heavy chain antibodies
Charan Kumar V. Devarakonda1, Daniel Kita1, Kathryn N. Phoenix1, Dewey M. Magee2, Kevin P. Claffey1. 1University of Connecticut Health Center, Farmington, CT; 2Arizona State University, Tempe, AZ


Bullboard Posts